Moderna-Merck Melanoma Vaccine Success Sparks mRNA Manufacturing and Market Shifts
Merck and Moderna reported that their personalized mRNA cancer vaccine, intismeran autogene, significantly improved recurrence-free survival when combined with Keytruda in a phase 3 melanoma trial. While the companies withheld detailed data, the results have boosted investor confidence and accelerated interest in personalized oncology. However, industry experts warn that commercializing these treatments requires overcoming complex manufacturing hurdles, as each vaccine must be custom-made for individual patients, unlike traditional mass-produced drugs.
